Blueprint Medicines (BPMC) PT Raised to $155 at Stifel
Stifel analyst Bradley Canino raised the price target on Blueprint Medicines (NASDAQ: BPMC) to $155.00 (from $150.00) while maintaining a ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)